CI5 - What does CI5 stand for? Acronyms and abbreviations by the Free Online Dictionary.

Acronym

Definition

CI5

Criminal Intelligence 5 (UK TV)

? References in periodicals archive
Table 3 VIGOR-Summary of Patients with Gastrointestinal Safety Events1 COMPARISON TO NAPROXEN VIOXX 50 mg Naproxen Relative GI Safety Endpoints daily 1000 mg Risk of 95% CI5 (N=4047)2 daily VIOXX n3 (N=4029)2 compared (Cumulative n3 to Rate4) (Cumulative naproxen5 Rate4) ---------------------------------------------------------------------- PUBs 56 (1. FDA Approves VIOXX for Once-Daily Treatment of Juvenile Rheumatoid ... by Business Wire Table 2 VIGOR-Summary of Patients with Gastrointestinal Safety Events1 COMPARISON TO NAPROXEN VIOXX 50 mg Naproxen Relative GI Safety Endpoints daily 1000 mg Risk of (N=4047)2 daily VIOXX n3 (N=4029)2 compared (Cumulative n3 to Rate4) (Cumulative naproxen5 95% CI5 Rate4) ---------------------------------------------------------------------- PUBs 56 (1. FDA Approves VIOXX for the Acute Treatment of Migraine in Adults; ... by Business Wire 22) ----------------------------------------------------------- -------------------- ------------------ --------------- Relative Risk of GI Safety Endpoints VIOXX compared 95% CI5 to naproxen5 -------------------- ------------------ --------------- PUBs 0. VIOXX Relieved Acute Migraine Pain in a New Investigational Study of ... by Business Wire More results

? References in periodicals archive

Table 3 VIGOR-Summary of Patients with Gastrointestinal Safety Events1 COMPARISON TO NAPROXEN VIOXX 50 mg Naproxen Relative GI Safety Endpoints daily 1000 mg Risk of 95% CI5 (N=4047)2 daily VIOXX n3 (N=4029)2 compared (Cumulative n3 to Rate4) (Cumulative naproxen5 Rate4) ---------------------------------------------------------------------- PUBs 56 (1.

FDA Approves VIOXX for Once-Daily Treatment of Juvenile Rheumatoid ... by Business Wire

Table 2 VIGOR-Summary of Patients with Gastrointestinal Safety Events1 COMPARISON TO NAPROXEN VIOXX 50 mg Naproxen Relative GI Safety Endpoints daily 1000 mg Risk of (N=4047)2 daily VIOXX n3 (N=4029)2 compared (Cumulative n3 to Rate4) (Cumulative naproxen5 95% CI5 Rate4) ---------------------------------------------------------------------- PUBs 56 (1.

FDA Approves VIOXX for the Acute Treatment of Migraine in Adults; ... by Business Wire

22) ----------------------------------------------------------- -------------------- ------------------ --------------- Relative Risk of GI Safety Endpoints VIOXX compared 95% CI5 to naproxen5 -------------------- ------------------ --------------- PUBs 0.

VIOXX Relieved Acute Migraine Pain in a New Investigational Study of ... by Business Wire

More results